Streetbeat News

Equity Actions

IFF

Analyst ratings for Intl Flavors & Fragrances (IFF) show diverse opinions with a recent shift towards more positive evaluations. Over the last three months, 11 analysts have provided ratings, with a notable increase in the average 12-month price target to $85.73, up 8.52% from $79.00. Recent actions include both upgrades and downgrades, reflecting dynamic market conditions and company performance. Despite the positive analyst sentiment, IFF faces financial challenges, including a -4.15% decline in revenue growth and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:00 pm

CE

Analyst ratings for Celanese (NYSE:CE) show varied perspectives, with recent adjustments reflecting a generally positive outlook. The average 12-month price target has increased to $162.5, up 11.63% from $145.57, indicating bullish sentiment. Despite a negative revenue trend of -5.66% as of December 31, 2023, Celanese's financial health remains strong with a high net margin of 27.17% and ROE of 10.28%. The company's debt-to-equity ratio of 1.98 suggests higher financial risk.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:00 pm

KTOS

Kratos Defense & Security Solutions announced a $300 million proposed public offering, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 4:52 pm

GBNH

Greenbrook TMS Inc (NASDAQ:GBNH) shares plummeted 44.5% to $0.21 after announcing a direct offering of 6 million shares at $0.20 each, aiming to raise $1.2 million for working capital and general purposes. A.G.P./Alliance Global Partners is the placement agent for the offering, expected to close on February 26.

Portfolio Pulse from Henry Khederian

February 22, 2024 | 4:20 pm

IBP

Installed Building Products (IBP) shares surged following the announcement of better-than-expected Q4 financial results and the authorization of a $300 million stock repurchase program.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 4:20 pm

WRAC

Williams Rowland Acquisition Corp. (WRAC) announced it will liquidate and dissolve, redeeming all outstanding public shares effective March 8, 2024, due to its inability to complete an initial business combination by March 29, 2024. The company will cease operations except for winding up, redeem public shares with funds from its trust account, and dissolve following stockholder and board approval. WRAC's securities will stop trading on the NYSE American on February 29, 2024, and it plans to delist and terminate the registration of its securities.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 4:18 pm

DPRO

Draganfly Inc. (NASDAQ:DPRO) shares plummeted by 48.4% to $0.18 after announcing a $3.6 million underwritten public offering at $0.27 per unit. The offering includes 13.4 million units, each comprising one common share (or pre-funded warrant) and one warrant to purchase one common share at $0.36, expiring in five years. Maxim Group LLC is managing the offering, with proceeds aimed at general corporate purposes, including product development and potential acquisitions. The offering is expected to close by February 26, subject to regulatory approvals.

Portfolio Pulse from Henry Khederian

February 22, 2024 | 4:16 pm

ON

The analysis of ON Semiconductor (NASDAQ:ON) compared to its competitors in the Semiconductors & Semiconductor Equipment industry reveals potential undervaluation based on its PE, PB, and PS ratios. Despite a high ROE indicating strong profitability, concerns arise from its low EBITDA, gross profit, and negative revenue growth. The company's lower debt-to-equity ratio suggests a stronger financial position relative to its top 4 peers.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 4:00 pm

HRMY

Analyst ratings for Harmony Biosciences (NASDAQ:HRMY) show mixed sentiments with a recent shift towards bullishness. The average 12-month price target has increased by 31.9% to $38.25. Analysts from Needham, Mizuho, Goldman Sachs, and B of A Securities have updated their ratings and price targets, reflecting changes in market conditions and company performance. Harmony Biosciences, a commercial-stage pharmaceutical company, has shown remarkable financial health with significant revenue growth, high net margin, and effective debt management.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 4:00 pm

AAPL

HPE

SMCI

Super Micro Computer (SMCI) is evaluated against competitors in the Technology Hardware, Storage & Peripherals industry. Despite a high P/E ratio and revenue growth, SMCI shows potential inefficiency in profit generation and operational efficiency. The company's financial metrics, including P/E, P/B, P/S ratios, and ROE, are compared with industry averages and competitors like Apple Inc, Hewlett Packard Enterprise Co, and others. SMCI's lower debt-to-equity ratio suggests a stronger financial position relative to its peers.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 4:00 pm